Trial Profile
A PHASE II,MULTI-CENTER, OPEN LABEL STUDY OF ORAL LBH589 PLUS MELPHALAN, PREDNISONE AND THALIDOMIDE (LB-MPT) IN ADVANCED, REFRACTORY MULTIPLE MYELOMA PATIENTS.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Mar 2022
Price :
$35
*
At a glance
- Drugs Panobinostat (Primary) ; Thalidomide (Primary) ; Melphalan; Prednisone
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 10 Mar 2022 Status changed from recruiting to completed.
- 25 Jul 2011 New trial record